Vertaling van "information about the marketing " (Nederlands → Frans) :

Information about the marketing of medicines (sunset clause) e-mail fagg-afmps.sunsetclause@fagg-afmps.be
Information about the marketing of medicines (sunset clause) e-mail fagg-afmps.sunsetclause@fagg-afmps.be

Sandoz: USD 538 million (–9%) Volume expansion in many key markets and ongoing productivity gains were more than offset by lower contributions from the US and negative currency movements of about 13 percentage points.
Sandoz: USD 538 millions (–9%) Un accroissement des volumes dans plusieurs marchés-clés et des gains de productivité continus ont été annihilés par une réduction des contributions provenant des Etats-Unis et par des changes défavorables à hauteur de treize points de pourcentage environ.

Omnitrope, the pioneering biosimilar of the recombinant human growth hormone somatropin, has received regulatory approval as the first-ever biosimilar in Japan under the brand name Somatropin BS S.C. This approval paves the way for greater access to high-quality biopharmaceuticals in the world’s second-largest pharmaceuticals market and comes about three months after Japanese authorities published guidelines for a biosimilar regulatory pathway, which is based on similar scientific principles already in place in the European Union.
Omnitrope, biosimilaire pionnier de la somatropine, une hormone de croissance humaine recombinante, a obtenu une autorisation au Japon sous la marque Somatropin BS S.C. Il s’agit du premier biosimilaire à avoir été homologué dans ce pays.

Diovan (USD 5.7 billion, +10% lc), the world’s top-selling branded medicine for high blood pressure, grew steadily in all key markets worldwide, with areas outside the US now accounting for about 58% of net sales and delivering 10% lc growth.
Diovan (USD 5,7 milliards, +10% en m. l.), médicament numéro un contre l’hypertension dans le monde, a enregistré une croissance régulière dans tous les marchés-clés.

It is also essential for rational and safe use of medicines that the information in advertising agrees with the elements approved of when the marketing authorisation (MA) for the medicine was granted. Healthcare professionals when making a therapeutic choice should not be influenced by elements that are not associated with the characteristics of the medicine.
It is also essential for rational and safe use of medicines that the information in advertising agrees with the elements approved of when the marketing authorisation (MA) for the medicine was granted. Healthcare professionals when making a therapeutic choice should not be influenced by elements that are not associated with the characteristics of the medicine.

In close cooperation with Mdeon, the FAMHP has mainly focused on the provision of information to the relevant parties, i.e. companies and healthcare professionals, during this first operational year A “contact point” collects and processes information about actions that may constitute an infringement of the legal requirements about advertising. In terms of advertising for healthcare professionals, attention is particularly being focused at present on the conformity of the legally required information
In close cooperation with Mdeon, the FAMHP has mainly focused on the provision of information to the relevant parties, i.e. companies and healthcare professionals, during this first operational year A “contact point” collects and processes information about actions that may constitute an infringement of the legal requirements about advertising. In terms of advertising for healthcare professionals, attention is particularly being focused at present on the conformity of the legally required information

- Contact) ●● Providing information about the legal context and procedures ●● Providing information about medicines and
- Contact) ●● Providing information about the legal context and procedures ●● Providing information about medicines and

In this context the FAMHP supports provision of pharmacotherapeutic information to care providers and has concluded partnerships with independent organisations providing objective information about medicines (for instance the Belgian Centre for Pharmacotherapeutic Information – BCFI-CBIP and Project Farmaka, not-for-profit organisations). This process needs to take into consideration the expectations of healthcare professionals in terms of information content on the one hand, and the ease of access and consultation of the data on the other.
In this context the FAMHP supports provision of pharmacotherapeutic information to care providers and has concluded partnerships with independent organisations providing objective information about medicines (for instance the Belgian Centre for Pharmacotherapeutic Information – BCFI-CBIP and Project Farmaka, not-for-profit organisations). This process needs to take into consideration the expectations of healthcare professionals in terms of information content on the one hand, and the ease of access and consultation of the data on the other.

The latter involves, on the one hand, the provision of relevant information about authorised medicines and health products aimed at the different target groups, and, on the other hand, the partnership with bodies responsible for the distribution of independent information, such as the BCFI - CBIP.
The latter involves, on the one hand, the provision of relevant information about authorised medicines and health products aimed at the different target groups, and, on the other hand, the partnership with bodies responsible for the distribution of independent information, such as the BCFI - CBIP.

The database can be used to look up extensive information about authorised medicines without having to contact those responsible for providing information, as is currently the case ●● Healthcare professionals and veterinarians
The database can be used to look up extensive information about authorised medicines without having to contact those responsible for providing information, as is currently the case ●● Healthcare professionals and veterinarians